Ocular sequelae of epidermal necrolysis: French national audit of practices, literature review and proposed management.
Drug reaction
Eye
Management
Ocular involvement
Sequelae
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Treatment
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
11 03 2023
11 03 2023
Historique:
received:
05
06
2022
accepted:
15
01
2023
entrez:
11
3
2023
pubmed:
13
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and rare diseases, most often drug-induced, and their incidence has been estimated at 6 cases/million/year in France. SJS and TEN belong to the same spectrum of disease known as epidermal necrolysis (EN). They are characterized by more or less extensive epidermal detachment, associated with mucous membrane involvement, and may be complicated during the acute phase by fatal multiorgan failure. SJS and TEN can lead to severe ophthalmologic sequelae. There are no recommendations for ocular management during the chronic phase. We conducted a national audit of current practice in the 11 sites of the French reference center for toxic bullous dermatoses and a review of the literature to establish therapeutic consensus guidelines. Ophthalmologists and dermatologists from the French reference center for epidermal necrolysis were asked to complete a questionnaire on management practices in the chronic phase of SJS/TEN. The survey focused on the presence of a referent ophthalmologist at the center, the use of local treatments (artificial tears, corticosteroid eye drops, antibiotic-corticosteroids, antiseptics, vitamin A ointment (VA), cyclosporine, tacrolimus), the management of trichiatic eyelashes, meibomian dysfunction, symblepharons, and corneal neovascularization, as well as the contactologic solutions implemented. Eleven ophthalmologists and 9 dermatologists from 9 of the 11 centers responded to the questionnaire. Based on questionnaire results, 10/11 ophthalmologists systematically prescribed preservative-free artificial tears, and 11/11 administered VA. Antiseptic or antibiotic eye drops or antibiotic-corticosteroid eye drops were recommended as needed by 8/11 and 7/11 ophthalmologists, respectively. In case of chronic inflammation, topical cyclosporine was consistently proposed by 11/11 ophthalmologists. The removal of trichiatic eyelashes was mainly performed by 10/11 ophthalmologists. Patients were referred to a reference center for fitting of scleral lenses (10/10,100%). Based on this practice audit and literature review, we propose an evaluation form to facilitate ophthalmic data collection in the chronic phase of EN and we also propose an algorithm for the ophthalmologic management of ocular sequelae.
Identifiants
pubmed: 36906580
doi: 10.1186/s13023-023-02616-6
pii: 10.1186/s13023-023-02616-6
pmc: PMC10007779
doi:
Substances chimiques
Lubricant Eye Drops
0
Cyclosporine
83HN0GTJ6D
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Informations de copyright
© 2023. The Author(s).
Références
Am J Ophthalmol. 1996 Jul;122(1):38-52
pubmed: 8659597
Ann Dermatol Venereol. 1985;112(11):883-8
pubmed: 3879142
J Cataract Refract Surg. 2007 Sep;33(9):1644-6
pubmed: 17720085
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES80-DES86
pubmed: 30481810
Ocul Surf. 2015 Jul;13(3):213-25
pubmed: 26045239
Curr Opin Ophthalmol. 2016 Nov;27(6):522-529
pubmed: 27585215
Am J Ophthalmol. 2009 Dec;148(6):852-9.e2
pubmed: 19837383
Am J Ophthalmol. 2014 Nov;158(5):983-93
pubmed: 25036881
J Fr Ophtalmol. 2010 Nov;33(9):630-6
pubmed: 21035899
Ophthalmology. 1988 Oct;95(10):1442-6
pubmed: 3067180
Curr Eye Res. 2011 Sep;36(9):775-81
pubmed: 21851164
Ocul Surf. 2016 Apr;14(2):168-88
pubmed: 26882981
Ocul Surf. 2003 Oct;1(4):192-201
pubmed: 17075650
Front Med (Lausanne). 2021 Jul 28;8:657327
pubmed: 34395463
Eur J Ophthalmol. 2014 May-Jun;24(3):299-308
pubmed: 24242219
Am J Ophthalmol. 2013 May;155(5):804-13
pubmed: 23394907
Am J Ophthalmol. 2021 Feb;222:82-91
pubmed: 32818447
Ophthalmology. 1987 Oct;94(10):1286-9
pubmed: 3684207
J Fr Ophtalmol. 2016 Nov;39(9):791-803
pubmed: 27742136
Br J Ophthalmol. 2021 Sep;105(9):1238-1243
pubmed: 32830126
Ophthalmology. 2005 May;112(5):904-12
pubmed: 15878074
Am J Ophthalmol. 2011 Oct;152(4):600-608.e1
pubmed: 21683334
Br J Dermatol. 2020 Mar;182(3):618-624
pubmed: 31396952
J Craniofac Surg. 2018 Sep;29(6):1531-1534
pubmed: 29762330
N Engl J Med. 2000 Jul 13;343(2):86-93
pubmed: 10891515
Cornea. 2013 Aug;32(8):1116-9
pubmed: 23665646
Lancet. 2017 Oct 28;390(10106):1996-2011
pubmed: 28476287
Cornea. 2013 Feb;32(2):155-60
pubmed: 22735310
J Ocul Pharmacol Ther. 2013 Apr;29(3):372-7
pubmed: 23289903
Br J Ophthalmol. 2001 Oct;85(10):1188-97
pubmed: 11567963
Br J Dermatol. 2019 Jul;181(1):212-213
pubmed: 30633324
Ophthalmology. 2005 Oct;112(10):1790-4
pubmed: 16102833
Orphanet J Rare Dis. 2020 Sep 22;15(1):259
pubmed: 32962748
Ocul Surf. 2012 Jan;10(1):15-25
pubmed: 22330056
Br J Ophthalmol. 2007 Aug;91(8):1048-53
pubmed: 17314145
Sci Rep. 2020 Mar 9;10(1):4353
pubmed: 32152391
BMC Ophthalmol. 2014 Aug 08;14:97
pubmed: 25102918
Arch Dermatol. 2009 Feb;145(2):157-62
pubmed: 19221260